checkAd
    Perspective Therapeutics Aktie
    1,6800
     
    USD
    +2,44 %
    +0,0400 USD
    Letzter Kurs 00:40:02 AMEX
    1,6900
     
    USD
    700 STK
    Geldkurs 30.04.24
    1,7000
     
    USD
    9.800 STK
    Briefkurs 30.04.24
    ISIN: US46489V1044 · WKN: A0MQNM · SYM: CATX · USA

    Neueste Nachrichten

    Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
    30.04.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics to Participate at Upcoming April Investor Conferences
    08.04.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
    28.03.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
    18.03.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
    11.03.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
    05.03.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics Announces $87.4 Million Private Placement
    04.03.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics to Participate at Upcoming Investor Conferences
    26.02.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    12.02.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
    01.02.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
    22.01.24 · globenewswire · Perspective Therapeutics
    Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
    18.01.24 · globenewswire · Perspective Therapeutics